FRM
ACHN

Fox Run Management’s Achillion Pharmaceuticals ACHN Stock Holding History

Fox Run Management’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-13,000
Closed -$105K – 753
2016
Q3 		$105K Sell
13,000
-400
-3% -$3.4K 0.06% 442
2016
Q2 		$105K Buy
+13,400
New +$115K 0.05% 503
2016
Q1 		– Sell
-22,000
Closed -$237K – 608
2015
Q4 		$237K Buy
+22,000
New +$200K 0.18% 255

Other funds holding ACHN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Fox Run Management's ACHN Position: Q4 2016 in Review

Fox Run Management sold out of Achillion Pharmaceuticals (ACHN) in Q4 2016, closing a stake of 13,000 shares — an estimated $105K sold.

Fox Run Management first reported a position in ACHN in Q4 2015 and held it in 3 quarters. The position peaked at $237K in Q4 2015. 140 funds tracked by Wall St. Rank hold ACHN as of Q4 2016.

  • Fox Run Management reported no remaining Achillion Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • Fox Run Management sold 13,000 Achillion Pharmaceuticals shares in Q4 2016, an estimated $105K.
  • Fox Run Management first reported a position in Achillion Pharmaceuticals in Q4 2015 and held it in 3 quarters.
  • Fox Run Management's Achillion Pharmaceuticals position peaked at $237K in Q4 2015.
  • 140 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q4 2016.

Based on Fox Run Management's 13F filing for Q4 2016, filed 10 Jan 2017.